http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26801886.html si-local-file:///var/storage/secattach/20260722/26801886.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26801886.html Wed, 22 Jul 2026 16:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26801886.html si-local-file:///var/storage/secattach/20260722/26801886.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26801886.html Wed, 22 Jul 2026 16:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+16/26776751.html si-local-file:///var/storage/secattach/20260716/26776751.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+16/26776751.html Thu, 16 Jul 2026 07:43:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+16/26776751.html si-local-file:///var/storage/secattach/20260716/26776751.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+16/26776751.html Thu, 16 Jul 2026 07:43:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Corporate+News/Galmed+develops+heart-targeted+nanoparticle+formulation+of+Aramchol/26776731.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has developed a lipid nanoparticle (LNP) formulation of its drug Aramchol designed to target heart tissue, the company announced in a press release dated July 16, 2026.</p><p>The formulation was developed in collaboration with Barcode Nanotech and uses FDA-approved lipids. According to the company, the traditional Aramchol formulation results in 80–90% accumulation in the liver. The new LNP formulation redirects Aramchol's biodistribution away from liver cells toward heart muscle tissue.</p><p>The development process involved in vivo screening and AI-enabled analysis to identify nanoparticle candidates with targeted cardiac delivery. The collaboration aims to direct the therapy to specific http://www.streetinsider.com/Corporate+News/Galmed+develops+heart-targeted+nanoparticle+formulation+of+Aramchol/26776731.html Thu, 16 Jul 2026 07:32:08 -0400 GLMD http://www.streetinsider.com/FDA/Galmed+develops+heart-targeted+nanoparticle+formulation+of+Aramchol/26776731.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has developed a lipid nanoparticle (LNP) formulation of its drug Aramchol designed to target heart tissue, the company announced in a press release dated July 16, 2026.</p><p>The formulation was developed in collaboration with Barcode Nanotech and uses FDA-approved lipids. According to the company, the traditional Aramchol formulation results in 80–90% accumulation in the liver. The new LNP formulation redirects Aramchol's biodistribution away from liver cells toward heart muscle tissue.</p><p>The development process involved in vivo screening and AI-enabled analysis to identify nanoparticle candidates with targeted cardiac delivery. The collaboration aims to direct the therapy to specific http://www.streetinsider.com/FDA/Galmed+develops+heart-targeted+nanoparticle+formulation+of+Aramchol/26776731.html Thu, 16 Jul 2026 07:32:08 -0400 GLMD http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/Press+Releases/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html <div class="xn-content"> <ul type="disc"><li>Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.</li><li>Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.</li><li>Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.</li><li>Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited http://www.streetinsider.com/PRNewswire/Galmed+Announces+the+Breakthrough+Development+of+Novel+LNP+Cardiac+Targeted+Formulation+of+its+SCD1+inhibitor%2C+Aramchol/26776694.html Thu, 16 Jul 2026 07:30:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+08/26747736.html si-local-file:///var/storage/secattach/20260708/26747736.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+08/26747736.html Wed, 08 Jul 2026 16:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+08/26747736.html si-local-file:///var/storage/secattach/20260708/26747736.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+08/26747736.html Wed, 08 Jul 2026 16:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html <p>Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.</p> <p>Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.</p> <p>Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange, http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html Tue, 07 Jul 2026 08:20:14 -0400 CHAI GLMD PLRZ http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html <p>Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.</p> <p>Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.</p> <p>Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange, http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html Tue, 07 Jul 2026 08:20:14 -0400 CHAI GLMD PLRZ http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html <p>Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.</p> <p>Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.</p> <p>Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange, http://www.streetinsider.com/Management+Changes/Core+AI+Holdings+names+Arie+Goor+as+CFO%2C+effective+July+1/26739051.html Tue, 07 Jul 2026 08:20:14 -0400 CHAI GLMD PLRZ http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Corporate+News/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX http://www.streetinsider.com/Management+Changes/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html <p>Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.</p><p>To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.</p><p>Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim http://www.streetinsider.com/Management+Changes/Imunon+names+new+interim+CFO+as+predecessor+retires/26714306.html Tue, 30 Jun 2026 16:40:36 -0400 BFRG GLMD IMNN INM TRPX